Reporting on a study of the reaction of children to morphine administration at SLEEP 2015, Gaspard Montandon, PhD, University of Toronto, said that respiratory depression was "more severe when patients were in states of reduced arousal due to the sedative properties of morphine."
Severe obstructive sleep apnea syndrome (OSAS) may potentially be associated with pancreatic β-cell functional disorder and glucagon-like peptide-1 (GLP-1) resistance, according to a study presented at SLEEP 2015.
Chewing caffeine gum for five minutes immediately upon awakening may counter sleep inertia, especially for reaction time, according to a data presented at SLEEP 2015.
Administration of a non-benzodiazepine sedative hypnotic (NBSH) does not increase the likelihood of having a low arousal phenotype for obstructive sleep apnea (OSA), a study presented at SLEEP 2015 has concluded.
The orexin receptor antagonist suvorexant improves sleep in patients with insomnia, analysis of pooled results of two Phase 3 clinical trials presented at SLEEP 2015 have found.
Lemborexant (E2006), a dual orexin receptor antagonist (DORA) under development for insomnia disorder, led to a decrease in latency to persistent sleep (LPS) and wake after sleep onset (WASO) and an increase in sleep efficiency (SE), according to data presented at SLEEP 2015.
Sodium oxybate improved health-related quality-of-life (HRQoL) measures in patients with narcolepsy in a dose-dependent manner, results from a randomized placebo-controlled trial presented at SLEEP 2015 have found.
Pharmacotherapy improves multiple domains of functioning in patients with central disorders of hypersomnolence (CDH) in a "real-world" tertiary care setting, according to data presented at SLEEP 2015.
A case study presented at SLEEP 2015 suggest that an influenza vaccination may have triggered status cataplecticus in the female patient with known narcolepsy.
Milnacipran does not directly improve sleep continuity and architecture but its impact on sleep improvement can be attributed to its effectiveness in reducing pain, according to data presented at SLEEP 2015.
When eszopiclone was given instead of zolpidem, no difference was observed on the polysomnogram diagnostic and positive airway pressure (PAP)-titration portions, according to data reported at SLEEP 2015.
An 80-year-old male with new onset myasthenia gravis and narcolepsy with cataplexy had symptomatic improvement with sodium oxybate—but not with immune-modulating agents, results of a case study presented at SLEEP 2015 have shown.
E2006, a novel dual orexin receptor antagonist (DORA), has shown efficacy for both subject-reported sleep onset and maintenance on sleep diary measures, according to Phase 2 study results reported at SLEEP 2015.
Almorexant, a hypocretin receptor antagonist, produced fewer acute cognitive effects than the GABAA receptor modulator zolpidem, according to results of a randomized controlled trial presented at SLEEP 2015.
Treatment with gabapentin enacarbil at both the 600mg and 1200mg doses "led to a greater number of adult patients who met the criteria for a combined pain and International Restless Legs Scale (IRLS) total score response" compared to placebo, a study presented at SLEEP 2015 confirmed.
For about one-third of patients treated with zolpidem, only partial improvement is observed, researchers reported at SLEEP 2015.
Higher levels of vitamin E improve spatial memory performance in sleep-deprived women, according to data presented at SLEEP 2015.
Suvorexant (Belsomra; Merck) 20mg/15mg and 40mg/30mg tablets were generally effective and well tolerated by both women and men with insomnia, according to a subgroup analysis of Phase 3 data presented at SLEEP 2015.
Clinician- and patient-reported assessments of global impression of change in disease status had "good concordance" for narcolepsy treated with JZP-110, a novel wake-promoting agent, according to results of a post hoc analysis reported at SLEEP 2015.
In patients with treatment-resistant nocturnal frontal lobe epilepsy (NFLE), lacosamide may be an effective option, researchers concluded at SLEEP 2015.
Further clinical investigation of the selective high affinity/potent dual orexin-2 receptor antagonist (OX2R) JNJ-42847922 is supported by preclinical and Phase 1 clinical data, a characterization of the agent presented at SLEEP 2015 has found.
Sodium oxybate (Xyrem; Jazz), alone or in combination with modafinil, improved excessive sleepiness in patients with narcolepsy both with and without cataplexy, results of a retrospective analysis of Phase 3 randomized trial data presented at SLEEP 2015 has found.
The first formal randomized, placebo-controlled trial to evaluate sodium oxybate for the treatment of children and adolescents with narcolepsy and cataplexy is currently enrolling patients (NCT02221869), investigators reported at SLEEP 2015.
The blocking of orexin signaling has been shown to reduce wakefulness and promote sleep across species, reported Christopher J. Winrow, PhD of Merck Research Laboratories, West Point, PA, at SLEEP 2015.
Potassium chloride supplementation might improve the severity of obstructive sleep apnea (OSA) and sleep architecture in hypertensive patients with hypokalemia, according to a study presented at SLEEP 2015.
Use of a combined oral contraceptive has shown to increase cortisol and adrenocorticotropic hormone concentrations, which are closely related with sleep, according to data presented at SLEEP 2015.